Nitroglycerin? Yes or No? That Is the Question! Risk of Administering Sublingual Nitroglycerin When the Patient Is Using Phosphodiesterase-5 Inhibitors.
St Paul, MN; New Wilmington, PA. Electronic address: somes@black-hole.com.
Joan
J
Somes
St Paul, MN; New Wilmington, PA.
Nancy Stephens
NS
Donatelli
D000286:Administration, Sublingual; D000368:Aged; D000369:Aged, 80 and over; D004347:Drug Interactions / Q000502:physiology; D016529:Emergency Nursing / Q000379:methods*; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D005996:Nitroglycerin / Q000008:administration & dosage / Q000009:adverse effects*; D058986:Phosphodiesterase 5 Inhibitors / Q000009:adverse effects*; D012306:Risk; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects*
D058986:Phosphodiesterase 5 Inhibitors; D014665:Vasodilator Agents; D005996:Nitroglycerin